US03152W1099 - Common Stock
11.86 -1.02 (-7.92%)
Premarket: 12.03 +0.17 (+1.43%)
AMICUS THERAPEUTICS INC
NASDAQ:FOLD (9/28/2023, 7:00:00 PM)Premarket: 12.03 +0.17 (+1.43%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Amicus Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 484 full-time employees. The company went IPO on 2007-05-31. The firm's portfolio is Galafold (migalastat), which is the approved oral precision medicine for people living with Fabry disease. Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in patients with genetic variants. Migalastat is approved under the trade name Galafold in the United States, European Union, United Kingdom and Japan. Its biologics program in its pipeline is Amicus Therapeutics GAA (AT-GAA), which is a clinical-stage treatment paradigm for Pompe disease. Pompe disease is a lysosomal disorder (LD) from deficiency in an enzyme, GAA. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221 (miglustat) that functions as an enzyme stabilizer.
AMICUS THERAPEUTICS INC
3675 Market Street
PHILADELPHIA PENNSYLVANIA 19104
CEO: John F. Crowley
Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults...
Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level.
Amicus Therapeutics expects imminent approval of its Pompe disease treatment, AT-GAA, as indicated in an updated corporate presentation.
Here you can normally see the latest stock twits on FOLD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.